Buspirone evidence

Buspirone is an anti-anxiety medication that works differently from both antidepressants and benzodiazepines. It acts mainly on serotonin receptors and is used primarily for generalized anxiety disorder.

Buspirone has been studied for generalized anxiety disorder since the 1980s, and controlled trials support a modest benefit over placebo for GAD symptoms. Its evidence base is strongest in GAD. Evidence in panic disorder and social anxiety disorder is weak, and buspirone isn't generally used as a primary treatment for those conditions.

Buspirone has two features that set it apart from benzodiazepines. It doesn't cause physical dependence, and stopping it doesn't produce a withdrawal syndrome. It also doesn't cause the sedation that benzodiazepines do. The trade-off is speed. Buspirone takes about two to four weeks to reach a clear effect, so it doesn't provide the rapid relief a benzodiazepine does.

Because of these features, buspirone is often used in specific situations rather than as a universal first choice. It's considered when an SSRI or SNRI isn't tolerated, as an add-on when an antidepressant has produced only a partial response, or for a patient for whom the dependence risk of a benzodiazepine is a particular concern. Clinical guidelines for GAD include buspirone as a recognized option.